📊 BDTX Key Takeaways
Investment Thesis
Black Diamond Therapeutics demonstrates exceptional financial health with strong profitability (32% net margin, 19.9% ROE) and excellent cash generation ($29.6M operating cash flow on $70M revenue). The company's net income surge of 132% YoY and pristine balance sheet ($112.2M equity, zero debt, 8.42x current ratio) indicate solid operational execution and financial stability, though revenue scale remains modest for a biotech company.
BDTX Strengths
- Exceptional profitability with 32.0% net margin and 17.9% operating margin indicating strong pricing power or operational efficiency
- Outstanding cash flow generation with $29.6M free cash flow and 42.3% FCF margin, providing runway for R&D and clinical trials
- Fortress balance sheet with $112.2M stockholders equity, zero long-term debt, and $21M cash providing financial flexibility
- Strong year-over-year growth in net income (+132.1%) and EPS (+130.7%) demonstrating improving profitability trajectory
- Exceptional liquidity with 8.42x current ratio indicating robust short-term financial health
BDTX Risks
- Limited revenue scale at $70M raises questions about competitive market position and market adoption for therapeutic products
- Gross margin data unavailable limiting visibility into cost of goods and manufacturing efficiency critical for biotech
- Modest revenue base creates vulnerability to product pipeline execution risk; single or few product dependence likely
- Operating margin dependent on revenue mix; any revenue decline would significantly impact profitability given fixed cost structure
- Biotech sector inherent risks including regulatory approvals, clinical trial outcomes, and competitive product introductions not reflected in historical metrics
Key Metrics to Watch
- Revenue growth trajectory and recurring revenue sustainability to assess market adoption and pipeline success
- Gross margin trends once available to evaluate manufacturing costs and operating leverage potential
- Cash burn rate and operating cash flow sustainability to determine runway for clinical development stage progression
- Debt/equity ratio monitoring given capital-intensive biotech requirements and potential financing needs
BDTX Financial Metrics
💡 AI Analyst Insight
The 42.3% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 8.42x current ratio provides a solid financial cushion.
BDTX Profitability Ratios
BDTX vs Healthcare Sector
How Black Diamond Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
BDTX Balance Sheet & Liquidity
BDTX 5-Year Financial Trend
5-Year Trend Summary: Black Diamond Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.27 indicates the company is currently unprofitable.
BDTX Growth Metrics (YoY)
BDTX Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$8.5M | $-0.15 |
| Q2 2025 | N/A | -$10.6M | $-0.19 |
| Q1 2025 | N/A | -$18.2M | $-0.35 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BDTX Capital Allocation
BDTX SEC Filings
Access official SEC EDGAR filings for Black Diamond Therapeutics, Inc. (CIK: 0001701541)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BDTX
What is the AI rating for BDTX?
Black Diamond Therapeutics, Inc. (BDTX) has an AI rating of BUY with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are BDTX's key strengths?
Exceptional profitability with 32.0% net margin and 17.9% operating margin indicating strong pricing power or operational efficiency. Outstanding cash flow generation with $29.6M free cash flow and 42.3% FCF margin, providing runway for R&D and clinical trials.
What are the risks of investing in BDTX?
Limited revenue scale at $70M raises questions about competitive market position and market adoption for therapeutic products. Gross margin data unavailable limiting visibility into cost of goods and manufacturing efficiency critical for biotech.
What is BDTX's revenue and growth?
Black Diamond Therapeutics, Inc. reported revenue of $70.0M.
Does BDTX pay dividends?
Black Diamond Therapeutics, Inc. does not currently pay dividends.
Where can I find BDTX SEC filings?
Official SEC filings for Black Diamond Therapeutics, Inc. (CIK: 0001701541) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BDTX's EPS?
Black Diamond Therapeutics, Inc. has a diluted EPS of $0.39.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.